Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience.

Bahap-Kara, Melda; Duran, Emine; Bayraktar-Ekincioglu, Aygin; Karadag, Omer

Bahap-Kara, Melda; Duran, Emine; Bayraktar-Ekincioglu, Aygin; Karadag, Omer.

Afiliação

Bahap-Kara M; Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Sihhiye, Ankara, Turkey. melda_610@hotmail.com.
Duran E; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Bayraktar-Ekincioglu A; Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Sihhiye, Ankara, Turkey.
Karadag O; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Intern Emerg Med ; 18(3): 791-799, 2023 04.

Article em En | MEDLINE | ID: mdl-36826744

Assuntos

Agamaglobulinemia; Medicamentos Biossimilares; Humanos; Rituximab/efeitos adversos; Medicamentos Biossimilares/efeitos adversos; Agamaglobulinemia/induzido quimicamente; Agamaglobulinemia/tratamento farmacológico; Estudos Retrospectivos; Resultado do Tratamento

Palavras-chave

Adverse events; Hypogammaglobulinemia; Infections; Infusion-related reactions; Interchangeability; Rituximab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Agamaglobulinemia / Medicamentos Biossimilares Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google